News from Our Members

October 18, 2017 - (Quad) - Quad Technologies announced today the U.S. Patent and Trademark Office has awarded the company a new U.S. Patent, No. 9,790,467, titled “Methods and Compositions for activation or expansion of T lymphocytes”. According to Quad Technologies CEO Sean Kevlahan, the patent relates to a scalable T-lymphocyte culture reagent that helps streamline CAR-T by eliminating the need for magnetic beads and the downstream “debeading” unit operation.
The new technology uses simple total cell count data from serially passaged cell cultures to decipher, for the first time, the specific number and functions of tissue stem cells in complex preparations like experimental or treatment samples. The desired data is extracted with proprietary computer simulation software developed with partner AlphaSTAR Corporation.
July 31, 2017 – (BioLife) – BioLife Solutions, Inc. announced it has executed a long term supply agreement with NASDAQ-listed Celyad, a leader in the discovery and development of CAR-T cell therapies. BioLife's CryoStor clinical grade cell freeze media is incorporated into Celyad's manufacturing process for its Natural Killer Receptor based T-Cell (NKR-T) platform. 
July 13, 2017 – (Novartis) – "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO, Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review." 
July 11, 2017 – (uniQure) – uniQure N.V. (NASDAQ:QURE) presented new clinical data demonstrating that the presence of pre-existing anti-AAV5 neutralizing antibodies does not predict the potential efficacy of AAV5-mediated gene transfer in patients with hemophilia B. 
July 11, 2017 – (BioMarin) – BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today an update to its previously reported interim results of an open-label Phase 1/2 study of BMN 270, an investigational gene therapy treatment for severe hemophilia A. 
July 10, 2017 – (CRISPR) – CRISPR Therapeutics (NASDAQ:CRSP) and Neon Therapeutics announced a research collaboration to explore the combination of each company’s proprietary technologies to develop novel T cell therapies. 

Pages